189955-95-1

Upstream product

• 224304-40-9 (2S,5S)-2-(tert-butyl)-5-ethyl-5-methyl-4-[4-(methylthio)-phenyl]-1,3-dioxolan-4-ol 
• 6192-52-5 p-toluenesulfonic acid monohydrate 

Downstream Products

• 224303-99-5 (5R)-5-ethyl-3-(4-fluorophenyl)-5-methyl-4-[4-(methylsulfonyl)phenyl ]-2,5-dihydro-2-furanone 
• 189954-83-4 (5R)-3-(4-Bromophenoxy)-5-ethyl-5-methyl-4-(4-methylsulfonyl)phenyl-5H-furan-2-one 
• 189955-02-0 (5R)-3-(4-Fluorophenoxy)-5-ethyl-5-methyl-4-(4-methylsulfonyl) phenyl-5H-furan-2-one 
• 189954-74-3 (5R)-3-(4-Chlorophenoxy)-5-ethyl-5-methyl-4-(4-methylsulfonyl)phenyl-5H-furan-2-one 
• 189957-47-9 (5R)-3-(5-chloro-2-pyridyloxy)-5-ethyl-5-methyl-4-(4-methylsulfonyl) phenyl-5H-furan-2-one 
• 189956-05-6 (1-cyclopropylethoxy)acetic acid 2(R)-methyl-1-(4-(methylsulfonyl)phenyl)butan-1-one-2yl ester 

Relevant academic research and scientific papers

An approach for the enantioselective synthesis of biologically active furanones from a Morita-Baylis-Hillman adduct

Herein, we disclose an approach for the asymmetric synthesis of both enantiomers of an anti-inflammatory furanone. The approach is based on the utilization of a Morita-Baylis-Hillman adduct as starting material and has as key step a selective epoxide-opening/benzylic oxidation mediated by Palladium (II). This sequence afforded an advanced intermediate, which was used to accomplish the total synthesis. Experimental evidences allowed us to suggest a mechanistic proposal for the oxidation Palladium(II)-mediated.

Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors

The invention encompasses compounds of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I e.g. (5R)-3-(3,4-difluorophenyl)-5-ethyl-5-methyl-4-[4-(methylsulfonyl)phenyl]-2,5-dihydro-2-furanone.